, as may glycoprotein markers such as CA15-3 (Tondini et al., 1988; Robertson et al., 1990) , MCA (Cooper et al., 1989; Laurence et al., 1991) and BCM (Daly et al., 1992 Robertson et al., 1991b ). This proportion is at least equivalent to that asable using the UICC criteria (Hayward et al., 1977) . In patients followed for response by the UICC criteria, the rsonse statuses at 6 months were highly and significntly correlated with the biochemical index at 2, 4 and 6 months.
Although March 1995. ments will require bone scans rather than skeletal surveys. Additional full blood counts and biochemistry will be required before each cycle of chemotherapy, which will be between therapeutic asssment vits.
For serm marker assesent at diagnosis, we presume that a chest radiography, bone scan and liver ultrasound would accompany the marker measurement. In reality, it is likely that only one imagi g test showing metastases would be required, and a patient's signs or symptoms would suggest the most appropriate form of investigation. However, to avoid overstatng the potential cost savings from the use of serum markers we shall include the use of all three imagi modalities for all patients. For follow-up assesments at 2, 4, 6, 9 and 12 months, only serum marker measures would be required.
Full blood counts and biochemistry will be required before each cycle of chemotherapy in both methods of assessment, although these are costs associated with therapy rather than assessment per se. In therapies guided by serum markers, it is assumed that skeletal radiographs would be used only to plan radiotherapy.
The gross cost savings estimated in this study arise from two sources. First, the serum markers assessment protocol, as specified above, emerges as being cheaper than the established UICC protocol for the monitoring of any given tumour and irrepective of any subsequent therapeutic intervention. Second, evidence suggests that serum markers at 2-4 months can accurately predict UICC assessment at 6 months (Robertson et al., 1991b) . Accordingly, we shall presume that the use of the serum markers protocol in place of UICC would permit the diagnosis of progressive disease at some earlier stage and would thus facilitate the earlier discontinuation of ineffective therapies. This, in turn, will yield savings in the cost of drugs administered.
As noted earLer, the projections rely upon experience accumulated in one particular institution. As information from a variety of clinical settings has yet to be generated, a simple ad hoc sensitivity analysis is employed to reveal a plausible range of costs saving to be anticipated. The selection of hormone therapy will be influenced by the Imenopausal status of the patients, and the pattern indicated reflects the recent patient distribution at the study site. Virtually all patients will receive a trial of hormone therapy at some period. Second-ine endocrine therapy will be used for We esimate that at least two-thirds will receive second-line hormone therapy. Third-line hormone therapy is usually rsrved for patients with tumours which have been shown to be endocrine sntive. Fifty per cent of patients respond or have static dises to first-line hormone therapy, of whom two-thirds will have a further period of remission in secondline endocrine therapy (Robertson et al., 1989) , i.e. one-third of the entire patient group. These patients should receve a trial of third-line endocrine therapy, and we have therefore used this number in our calculations. This is almost certainly an underestimte as, in elderly patients, endocrine therapy is often ni even when the chances of remission are small.
Res
The alternative first-line chemotherapy regimens are cyclophosphamide, methotrexate and 5-flurouracil (CMF) or mitoxantrone, methotrexate and mitromycin C (MMM). MMM would only be used as first-line chemotherapy for advanced breast cancer if CMF had been used as adjuvant therapy. For chemotherapy-naive patients, the much cheaper CMF would be preferred as the first-line regimen on diagnosis of advanced disease. The choice of second-ie chemotherapy is related to which agents were employed in first-line therapy.
As indicated, these savings are estumated on the basis of the proportion of patients in whom the tumours will be progressng and for whom the eariier assessment facilitated by serum markers will lead to arlier treatment discontinuation. We have presumed a 2 month saving in each case. Given the variation in the length of courses of therapy, we have sandardised all unit costs onto a monthly basis. The average cost of antiemetics in both cases has been estimated from the empirical observation that 40% of patients required ondansetron with dexamethasone (at £75.6 per cycle), 40% received maxolon (at only 0.33 p per course), while the mainder received no antiemetic therapy. The antiemetic cost included in Table II is thus the weighted average of the above.
To test the ensitivity of these results to parameter variation, we might vary, by 10%, first the proportion of patients receiving the cheaper drugs (implying corresponding changes to the proportion receiving the more expensve) and, second, the proportion of patients progesng as identified earlier by the serum markers. These assumptions yield treatnt savings per patient per year in the range £67.61-£81.16 for hormone therapy, £118.71-£176.76 for first-line chemotherapy and £448.09-£5i60.66 for second-he chemotheapy.
Median patient survival after the diagnosis of relapse is around 2 years . To obtain some notion of aggregate potential cost saving over a patient's expected lifetime, we shall assume that a patient with diagnosed metastatic breast cancer is monitored over 2 years usng serum markers as opposed to the UICC criteria. Most units will exhaust hormone therapy where appropriate for patients with metastatic disas before tuming to chemotherapy although, in some patients, chemotherapy will be used initially. For the purposes of this ilustration, we presume that hormone therapy is the systemic anti-cancer therapy for the first 12 months, and is thereafter replaed by chemotherapy. By 16 months, patients will be equally divide between first-ie and second-line chemotherapy. By 20 months, 90% will have moved to second-ine, the proportion rising to 100% by 24 months. For each time period, the estimated cost savigs apply. For the regimen outlined in (de Koning et al., 1992; Hurley et al., 1992; Richards et al., 1993 It must again be stressed that our estimates of cost savings are valid only within the confines of the model's assumptions and the data collected at Nottingham. It accordingly remains to be demonstrated more rigorously that the outcomes of serum marker assessment are at least as reliable as those of UICC and that our cost estimates are applicable to hospitals in general. Such a demonstration would only be possible as a result of a multicentre, randomised controlled trial, comparing two groups of patients treated on the basis of either UICC or tumour marker assessment. The magnitude of the projected cost savings certainly supports the case for such a trial; indeed, based on our estimates, even a large, multicentre trial could pay for itself in a matter of weeks.
